Tislelizumab and Induction Chemotherapy Followed by Radiotherapy or Adaptive Surgery for Larynx Preservation in Resectable Locally Advanced Laryngeal or Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Tislelizumab (Primary) ; Cisplatin; Docetaxel
- Indications Hypopharyngeal cancer; Laryngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2024 New trial record